LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.43 -1.62

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.39

Max

2.5

Belangrijke statistieken
By Trading Economics
Inkomsten	-27M -17M
Verkoop	586K 718K
EPS	-0.125
Winstmarge	-2,366.017
Werknemers	23
EBITDA	-5.5M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+115.79% upside

Dividenden
By Dow Jones
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-25M 458M
Vorige openingsprijs	4.05
Vorige sluitingsprijs	2.43

Nieuwssentiment

By Acuity

50%

154 / 344 Rangschikking in Healthcare

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mei 2026, 16:52 UTC

Belangrijke Nieuwsgebeurtenissen

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q EPS $11.61 >WEBC

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q Sales $179.6M >WEBC

26 mei 2026, 21:48 UTC

Marktinformatie

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mei 2026, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

26 mei 2026, 20:58 UTC

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 19:22 UTC

Marktinformatie

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mei 2026, 19:17 UTC

Marktinformatie

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mei 2026, 18:56 UTC

Marktinformatie

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mei 2026, 18:03 UTC

Marktinformatie

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mei 2026, 17:42 UTC

Marktinformatie

Grains Await Fresh Trading Catalyst -- Market Talk

26 mei 2026, 17:33 UTC

Marktinformatie

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mei 2026, 17:21 UTC

Marktinformatie

Canada Faces a Labor Market Squeeze -- Market Talk

26 mei 2026, 16:52 UTC

Marktinformatie

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mei 2026, 16:43 UTC

Marktinformatie

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mei 2026, 16:24 UTC

Marktinformatie

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mei 2026, 16:21 UTC

Marktinformatie

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

26 mei 2026, 16:16 UTC

Marktinformatie

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mei 2026, 16:01 UTC

Marktinformatie

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mei 2026, 15:21 UTC

Marktinformatie

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

115.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.33 USD 115.79%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

154 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.